Dabos KJ. New markers of fibrosis in hepatitis C: A step towards the Holy Grail? World J Hepatol 2024; 16(2): 112-114 [PMID: 38495275 DOI: 10.4254/wjh.v16.i2.112]
Corresponding Author of This Article
Konstantinos John Dabos, MD, PhD, Doctor, Department of Hepatology, St Hohn's Hospital, Howden Road West, Livingston EH54 6PP, West lothian, United Kingdom. konstantinos.dabos@nhslothian.scot.nhs.uk
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Feb 27, 2024; 16(2): 112-114 Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.112
New markers of fibrosis in hepatitis C: A step towards the Holy Grail?
Konstantinos John Dabos
Konstantinos John Dabos, Department of Hepatology, St Hohn's Hospital, Livingston EH54 6PP, West Lothian, United Kingdom
Author contributions: Dabos KJ wrote the manuscript.
Conflict-of-interest statement: Konstantinos Dabos declares no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Konstantinos John Dabos, MD, PhD, Doctor, Department of Hepatology, St Hohn's Hospital, Howden Road West, Livingston EH54 6PP, West lothian, United Kingdom. konstantinos.dabos@nhslothian.scot.nhs.uk
Received: November 15, 2023 Peer-review started: November 15, 2023 First decision: December 5, 2023 Revised: December 12, 2023 Accepted: January 12, 2024 Article in press: January 12, 2024 Published online: February 27, 2024 Processing time: 104 Days and 1.6 Hours
Abstract
In the present issue of the World Journal of Hepatology, Ferrassi et al examine the problem of liver fibrosis staging in chronic hepatitis C. They identify novel biomarkers in an effort to predict accurate fibrosis staging with the aid of the metabolome of Hepatitis C patients. Overall I think Ferrassi et al took a different approach in identifying fibrosis biomarkers, by looking at the patients’ metabolome. Their biomarkers clearly separate patients from controls. They can also separate out, patients with minimal fibrosis (F0-F1 stage) and patients with cirrhosis (F4 stage). Obviously, if these biomarkers were to be widely used, tests for all the important metabolites would need to be readily available for use in hospitals or outpatient setting and that may prove difficult and above all, costly. Nevertheless, this step could eventually lead to a metabolomic approach for novel biomarkers of Fibrosis. Obviously, it would need to be validated, but could represent a step towards the Holy Grail of Hepatology.
